<SEC-DOCUMENT>0001279569-19-001488.txt : 20190708
<SEC-HEADER>0001279569-19-001488.hdr.sgml : 20190708
<ACCEPTANCE-DATETIME>20190708163708
ACCESSION NUMBER:		0001279569-19-001488
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190708
FILED AS OF DATE:		20190708
DATE AS OF CHANGE:		20190708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		19945656

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0 3pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16 </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of July 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410 </B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway, Vancouver,
British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT>
Form 40-F <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>EXHIBITS INCLUDED AS PART OF THIS REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 6%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 94%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%"><B>Exhibit</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><A HREF="ex991.htm">News Release: ESSA Provides Update on Court Hearing</A></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT>
        <FONT STYLE="font-size: 10pt">P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT> <FONT STYLE="font-size: 10pt">I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt; line-height: 107%">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt; line-height: 107%">Date: July 8, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt; line-height: 107%">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT> <FONT STYLE="font-size: 10pt">W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 8, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;<IMG SRC="essalogo.jpg" ALT="" STYLE="width: 273px; height: 123px"></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA Provides Update on Court Hearing</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">VANCOUVER and HOUSTON, July 8, 2019 /CNW/ -
ESSA Pharma Inc. (&quot;<B>ESSA</B>&quot; or <B>&quot;the Company</B>&quot;) (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company
focused on developing novel therapies for the treatment of prostate cancer, announces that the hearing at the High Court of Justice
in England and Wales (the &quot;<B>Court</B>&quot;) in respect of the proposed scheme of arrangement under Part 26 of the U.K.
Companies Act 2006 (the &quot;<B>Scheme</B>&quot;), pursuant to which ESSA will acquire all of the issued and outstanding shares
of Realm Therapeutics plc (&quot;<B>Realm</B>&quot;), took place today in London.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Court reserved judgment and, as such, the
Court has not yet rendered its decision upon the sanctioning of the Scheme.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">As a consequence of the reserved judgment,
there is likely to be an update to the expected timetable of principal events for the implementation of the Scheme from that set
out in the announcement made by the Company on June 26, 2019. The Company will release an announcement as soon as reasonably practicable
following receipt of the Court's judgment and will include an updated timetable of principal events as applicable.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Unless otherwise defined herein, capitalized
terms and expressions used in this announcement shall have the meanings given to them in the scheme document published by Realm
on May 29, 2019.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About ESSA Pharma Inc.</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">ESSA is a pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer (&quot;CRPC&quot;) in patients
whose disease is progressing despite treatment with current therapies. ESSA's proprietary &quot;aniten&quot; compounds bind to
the N-terminal domain of the androgen receptor (&quot;AR&quot;), inhibiting AR-driven transcription and the AR signaling pathway
in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently
progressing IND-enabling studies and expects to enter clinical studies with EPI-7386 in the first calendar quarter of 2020. For
more information, please visit www.essapharma.com or follow us on Twitter under ESSA Pharma.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Prostate Cancer</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Prostate cancer is the second-most commonly
diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the
prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal
treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels
of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant
of the disease, metastatic CPRC (&quot;<B>mCRPC</B>&quot;), and most patients ultimately succumb to the illness. The treatment
of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed
to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This release contains certain information which,
as presented, constitutes &quot;forward-looking information&quot; within the meaning of the Private Securities Litigation Reform
Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events
and often addresses expected future business and financial performance, containing words such as &quot;look forward&quot;, &quot;anticipate&quot;
and, &quot;believe&quot;, and statements that an action or event &quot;is expected&quot;, &quot;is predicted&quot;, &quot;should&quot;,
&quot;may&quot; or &quot;will&quot; be taken or occur, or other similar expressions and includes, but is not limited to, statements
regarding the timing and completion of the Scheme.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking statements and information
are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict,
and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied
thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such
statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties
and contingencies. In making forward-looking statements, ESSA may make various material assumptions, including but not limited
to (i) the Court's sanction of the Scheme; (ii) the accuracy of ESSA's financial projections; (iii) obtaining positive results
of clinical trials; (iv) obtaining necessary regulatory approvals; and (v) general business, market and economic conditions.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Forward-looking information is developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated
December 13, 2018 under the heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile on the SEDAR website
at www.sedar.com or ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR and EDGAR
profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements
are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other
circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned
against attributing undue certainty to forward-looking statements.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><I>Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.</I></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.gif" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content:http://www.prnewswire.com/news-releases/essa-provides-update-on-court-hearing-300881043.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content: http://www.newswire.ca/en/releases/archive/July2019/08/c8115.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001633932</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Contact Information: Company: Peter
Virsik, Chief Operating Officer, ESSA Pharma Inc., Contact: (778) 331-0962; Investor Relations: Alan Lada, Solebury Trout, Contact:
(617) 221-8006, Email: alada@soleburytrout.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 15:39e 08-JUL-19</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJM&=)VD=5'$0JJ\2W11161L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?*NI?\A:]_Z^)/\ T(U]55\JZE_R%KW_
M *^)/_0C7IY9O+Y'DYKM'YE:BBKFEZ9=ZSJ4.GV2*]S,2$5F"@X!)Y/L#7K-
MI*[/&2;=D4Z*[+_A5GBS_GR@_P# E*/^%6>+/^?*#_P)2LOK%'^9&WU6M_*S
MC:*[+_A5GBS_ )\H/_ E*/\ A5GBS_GR@_\  E*/K%'^9!]5K?RLXVBNR_X5
M9XL_Y\H/_ E*/^%6>+/^?*#_ ,"4H^L4?YD'U6M_*SC:](^#'_(R:A_UZ?\
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MY'SA17H^K?![5K8L^EWD%['V23]V_P#@?S%<5J/A[6=()%_IEU !_&T9*_\
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MB;GDOQEUO+V.AQ-P/])G /U"#_T(_E7E%:?B+5WU[Q#?:DV<3RDH#V0<*/R
MK,KZ/#TO9TU$^6Q-7VM5R"O;?A!HWV/P]/JDBXDOI,(?^F:<#\SN_2O&+2UE
MOKV"T@&9IY%C0>Y.!7T]:6]MH>BPVX81VUG %+'LJCD_UKDS*JHTU'O^2.S*
MZ+G4<^WYLOYJ+[5;[]GGQ[_[N\9KR3Q#XPOM9G>."5[>QSA8U.&<>K$?RKF\
M<Y[U\96SJ$96IQNNY^A8?ARI.'-5GROM:_WGT)FO/OBYH_V[PQ'J,:YEL)-Q
M/_3-N&_7:?PKG?#_ (NO]%G1))'N++.'B<Y*CU4GI].E>K31VNMZ/)'D26MY
M"5R.ZL/_ *]>GEV80K24XZ-;H\7-LIJX:+A/52V?];,^6:*L7]E+INHW-C.,
M2V\K1-[D'%5Z^Q3NKH^%:L[,]2^#>M^5>7NB2O\ +,/M$(/]X<,!]1@_@:]A
MKY;T35)-$URRU*/.;>4.0/XEZ,/Q&17U!!-'<V\<\3!HY5#HP[@C(->+F%+E
MJ<ZZGNY;5YJ?(^A)1117 >D%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[6_V3WKYQU72KW1=0DL=0@:&=.H/1AZ@]P?6OJ>LCQ!X:TSQ+9?9M1@#[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A#  , '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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" #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
